K.C. v. Individual Members of the Medical Licensing Board

CourtCourt of Appeals for the Seventh Circuit
DecidedNovember 13, 2024
Docket23-2366
StatusPublished

This text of K.C. v. Individual Members of the Medical Licensing Board (K.C. v. Individual Members of the Medical Licensing Board) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
K.C. v. Individual Members of the Medical Licensing Board, (7th Cir. 2024).

Opinion

In the

United States Court of Appeals For the Seventh Circuit ____________________ No. 23-2366 K.C., et al., Plaintiffs-Appellees,

v.

INDIVIDUAL MEMBERS OF THE MEDICAL LICENSING BOARD OF INDIANA, et al., Defendants-Appellants. ____________________

Appeal from the United States District Court for the Southern District of Indiana, Indianapolis Division No. 1:23-cv-00595-JPH-KMB — James P. Hanlon, Judge. ____________________

ARGUED FEBRUARY 16, 2024 — DECIDED NOVEMBER 13, 2024 ____________________

Before RIPPLE, BRENNAN, and JACKSON-AKIWUMI, Circuit Judges. BRENNAN, Circuit Judge. Indiana enacted a law prohibiting its physicians from altering a child’s sex characteristics through medication or surgery as treatment for gender dys- phoria. Some children who would receive the treatment if not for the law argue that Indiana has deprived them of equal pro- tection of the laws based on their sex or transgender status. 2 No. 23-2366

The parents argue it infringes a fundamental right to oversee their children’s medical care because the law makes their con- sent legally irrelevant. And a physician argues Indiana’s deci- sion to extend enforcement to those who facilitate the banned treatment regulates her speech based on its content. The dis- trict court found that these arguments were likely to succeed and that a preliminary injunction was warranted. The state has appealed. Courts have long permitted states to hold closely the power to regulate the practice of medicine. This power is strongest when the safety and effectiveness of the treatment is uncertain, as is true here. This appeal calls us to decide whether the Constitution says a regulation of the treatments for gender dysphoria is a step too far, withdrawing the ques- tion from the people forever. I. A. Clinical treatment of minors with puberty blockers and hormone therapy At issue here are two medical treatments: puberty block- ers, which delay the onset of puberty, and hormone therapy, which introduces one of the primary sex hormones into the body’s endocrine system. For years, physicians working with children have used these treatments for disorders of sex de- velopment or puberty. More recently, physicians have begun using them to treat childhood gender dysphoria. Used in their traditional setting, puberty blockers and hor- mone therapy correct a pubertal or hormonal abnormality. For example, puberty blockers are a common treatment for central precocious puberty, which occurs when puberty be- gins too early. See Kanthi Bangalore Krishna et al., Use of No. 23-2366 3

Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium, 91 HORMONE RSCH. IN PÆDIATRICS 357, 357 (2019); Jadranka Popovic et al., Gonadotropin-Releasing Hormone Analog Therapies for Children with Central Precocious Puberty in the United States, 10 FRONTIERS IN PEDIATRICS, at 1, 2 (2022). Early onset of puberty can lead to serious physical con- sequences for the child, including shorter-than-expected height due to rapid acceleration of the skeleton, as well as be- havioral difficulties. Popovic, Gonadotropin-Releasing Hormone Analog Therapies, at 2. By slowing puberty down, puberty blockers can allow a child to begin puberty at an appropriate age and avoid these problems. Id. Another example is Klinefelter syndrome, which physi- cians sometimes treat with hormone therapy. This syndrome is a sex chromosome abnormality that affects boys. See Chang et al., Morbidity in Klinefelter Syndrome and the Effect of Testos- terone Treatment, 184 AM. J. OF MED. GENETICS 344, 344 (2020). Although they enter puberty normally, these boys can expe- rience an early cessation of puberty due to declining levels of testosterone. Anna Nordenström, Puberty in Individuals with a Disorder of Sex Development, 14 CURRENT OP. IN ENDOCRINE & METABOLIC RSCH. 42, 46 (2020). Klinefelter syndrome has been treated with testosterone supplementation since the 1960s, and hormone therapy has been proposed as a treatment since the 1940s, when Klinefelter was first described. Chang, Mor- bidity in Klinefelter Syndrome, at 344–45. More recently, physicians have started using puberty blockers and hormone therapy for a new purpose: to treat gender dysphoria in minors approaching puberty. Gender dysphoria is the diagnostic term for the distress a person may feel in response to believing their gender identity does not 4 No. 23-2366

match their sex. AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STA- TISTICAL MANUAL OF MENTAL DISORDERS 511 (5th ed. text revi- sion 2022). There are psychological and medical treatments for gen- der dysphoria. Social support and psychotherapy are widely recognized approaches, Danyon Anderson et al., Gender Dys- phoria and Its Non-Surgical and Surgical Treatments, 10 HEALTH PSYCH. RSCH., at 4 (2022), including by both appellees and ap- pellants. Medical organizations that broadly support inter- ventions endorse psychosocial therapy for gender dysphoria. Id. (“The WPATH recognizes that psychotherapy successfully helps individuals with their gender identity without needing hormone based medical therapy or gender affirmation sur- gery.”). Physicians may also attempt to eliminate the distress asso- ciated with gender dysphoria through three medical interven- tions relevant here. In adolescents, this route typically begins when a physician prescribes puberty blockers to prevent the development of secondary sex characteristics. Then, physi- cians can introduce the hormones biologically produced by the opposite sex to induce those secondary sex characteristics. And finally, a patient could undergo surgery to eliminate the primary sex characteristics developed in utero and establish the characteristics of the other sex through plastic surgery. The efficacy and risks of the three medical interventions are unclear. Some reports and studies provide reasons to be cautious, emphasizing the medical interventions’ usefulness in effectuating a gender transition but not in treating the men- tal health component. For example, one study found no “clin- ically significant changes” in depression and anxiety among minors prescribed hormone therapy within seven months of No. 23-2366 5

their first visit. Annette L. Cantu et al., Changes in Anxiety and Depression from Intake to First Follow-Up Among Transgender Youth in a Pediatric Endocrinology Clinic, 5 TRANSGENDER HEALTH 196, 199 (2020). Other reports have noted the risks and side effects of interfering with puberty, one of the most critical developmental periods in a human being’s life, when the gender dysphoria could be treated by other means. For example, a case study explored the devastating impacts on fertility and bone density in long-term use of puberty block- ers. Ken C. Pang et al., Long-term Puberty Suppression for a Non- binary Teenager, 145 PEDIATRICS, Feb. 2020, at 1, 2. Other sources support medical interventions, saying they do treat the mental health symptoms effectively and that the side effects are comparable whether or not prescribed as treat- ment for gender dysphoria. One study, for example, found a statistical correlation between gender hormone therapy and lower suicidality. Amy E. Green et al., Association of Gender- Affirming Hormone Therapy With Depression, Thoughts of Sui- cide, and Attempted Suicide Among Transgender and Nonbinary Youth, 70 J. ADOLESCENT HEALTH 643, 647 (2022). But the most influential voices in this group have been two professional organizations—the Endocrine Society and the World Profes- sional Association for Transgender Health. They have prom- ulgated treatment guidelines recommending that physicians use puberty blockers and hormone therapy to treat children with gender dysphoria at certain stages and after certain as- sessments. But these organizations have not evaded criticism.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Stevens
559 U.S. 460 (Supreme Court, 2010)
United States v. Villanueva
408 F.3d 193 (Fifth Circuit, 2005)
Union Pacific Railway Co. v. Botsford
141 U.S. 250 (Supreme Court, 1891)
Minnesota Ex Rel. Whipple v. Martinson
256 U.S. 41 (Supreme Court, 1921)
Meyer v. Nebraska
262 U.S. 390 (Supreme Court, 1923)
Snyder v. Massachusetts
291 U.S. 97 (Supreme Court, 1934)
Ashwander v. Tennessee Valley Authority
297 U.S. 288 (Supreme Court, 1936)
Cantwell v. Connecticut
310 U.S. 296 (Supreme Court, 1940)
Prince v. Massachusetts
321 U.S. 158 (Supreme Court, 1944)
Goesaert v. Cleary
335 U.S. 464 (Supreme Court, 1948)
Giboney v. Empire Storage & Ice Co.
336 U.S. 490 (Supreme Court, 1949)
Williamson v. Lee Optical of Oklahoma, Inc.
348 U.S. 483 (Supreme Court, 1955)
Robinson v. California
370 U.S. 660 (Supreme Court, 1962)
United States v. O'Brien
391 U.S. 367 (Supreme Court, 1968)
Dandridge v. Williams
397 U.S. 471 (Supreme Court, 1970)
Reed v. Reed
404 U.S. 71 (Supreme Court, 1971)
Frontiero v. Richardson
411 U.S. 677 (Supreme Court, 1973)
Marshall v. United States
414 U.S. 417 (Supreme Court, 1974)

Cite This Page — Counsel Stack

Bluebook (online)
K.C. v. Individual Members of the Medical Licensing Board, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kc-v-individual-members-of-the-medical-licensing-board-ca7-2024.